A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)

This Phase 2 study aims to evaluate whether Bruton's tyrosine kinase (BTK) inhibition with remibrutinib can produce a clinically meaningful reduction in inflammatory lesions in adults with moderate-to-severe papulopustular rosacea, while also assessing safety and tolerability of remibrutinib in this indication.

NCT Number	NCT07681271
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Papulopustular Rosacea
Enrollment	80 participants
Start Date	2026-07-29
Primary Completion	2027-12-07 (estimated)
Study Completion	2027-12-07 (estimated)
Updated on ClinicalTrials.gov	2026-07-02